Updated Version 2 - US FDA approves Inovio's therapy for rare respiratory disease; stock price surges

Stock information added in paragraph 2; detailed information provided in paragraph 3.

Reuters, October 30 - The U.S. Food and Drug Administration (FDA) said on Friday it has approved Inovio Pharmaceuticals' therapy for treating a rare respiratory disease, INO.O, marking the company's first approved product.

Inovio's stock price surged 215% in after-hours trading.

Inovio’s therapy, INO-3107 (brand name Voceryq), offers a new treatment option for patients with recurrent respiratory papillomatosis. This disease causes growths in the airway, often requiring repeated surgeries.

(To benefit non-native English speakers, Reuters has automated translation of its reports into several other languages. Because automated translation may contain errors or lack needed context, Reuters does not guarantee the accuracy of the automated translated text, which is provided for reader convenience only. Reuters accepts no liability for any damage or loss resulting from the use of automated translation functionality.)